Details for Patent: 11,628,162
✉ Email this page to a colleague
Which drugs does patent 11,628,162 protect, and when does it expire?
Patent 11,628,162 protects PEMAZYRE and is included in one NDA.
This patent has one patent family member in one country.
Drugs Protected by US Patent 11,628,162
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Incyte Corp | PEMAZYRE | pemigatinib | TABLET;ORAL | 213736-001 | Apr 17, 2020 | RX | Yes | No | 11,628,162 | ⤷ Subscribe | TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FGFR2 FUSION OR OTHER REARRANGEMENT BY ADMINISTERING PEMIGATINIB WHILE AVOIDING THE CONCOMITANT USE OF STRONG AND MODERATE CYP3A INHIBITORS | |||||
Incyte Corp | PEMAZYRE | pemigatinib | TABLET;ORAL | 213736-001 | Apr 17, 2020 | RX | Yes | No | 11,628,162 | ⤷ Subscribe | TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FGFR2 FUSION OR OTHER REARRANGEMENT BY ADMINISTERING PEMIGATINIB WHILE AVOIDING THE CONCOMITANT USE OF STRONG AND MODERATE CYP3A INDUCERS | |||||
Incyte Corp | PEMAZYRE | pemigatinib | TABLET;ORAL | 213736-001 | Apr 17, 2020 | RX | Yes | No | 11,628,162 | ⤷ Subscribe | TREATMENT OF RELAPSED OR REFRACTORY MYELOID/LYMPHOID NEOPLASMS WITH FGFR1 REARRANGEMENT BY ADMINISTERING PEMIGATINIB WHILE AVOIDING THE CONCOMITANT USE OF STRONG AND MODERATE CYP3A INDUCERS | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |
International Family Members for US Patent 11,628,162
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
World Intellectual Property Organization (WIPO) | 2020185532 | ⤷ Subscribe | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |